Get started

Stockstrading

Why CNET 3D-Printing Stock Soared YesterdayShares of 3D-printing companies rose sharply on Thursday after 3D Systems (NYSE:DDD) reported blockbuster preliminary results for the fourth quarter. This news has given investors hope that other companies in the sector will report similarly strong results. in the first three quarters of 2020, Stratasys's total revenue fell by more than 20% year over year. The strong preliminary results from 3D Systems are sparking investor optimism that the 3D-printing industry is about to come roaring back as manufacturing activity picks up and economies start to recover from the havoc caused by the pandemic. www.fool.com
NASDAQ:SSYS
by AlenCiken
SOS to Expand into Digital Assets Security IndustryDr. Huazhong (Eric) Yan A Renowned Cryptocurrencies Security Expert Joins SOS to Spearhead SOSs Effort to Expand into Digital Assets Security Industry Dr. Yan is expected to utilize his cryptocurrency mining, protection, insurance expertise and his industry resources to lead SOS's efforts to set up a new business to apply blockchain-based security and insurance technologies in the safeguard of cryptocurrencies and digital assets, and strategically upgrade SOS's existing portfolios of products and services. SOS plans to set up a new wholly owned subsidiary SOS Digital Technologies Inc., to be led by Dr Yan. SOS anticipates to utilize the new subsidiary to be spearheaded by Dr. Yan to provide the infrastructure services in blockchain security for its big data insurance marketing and rescue services, and even providing insurance and banking services for digital assets and cryptocurrencies. Dr Yan has applied seven patents in China related to decentralized cryptocurrency wallets and exchanges, the protections and insurance for digital assets and cryptocurrencies, and blockchain-based security framework and solutions. The truly decentralized cryptocurrency wallet and exchange technologies developed by Dr Yan have been proven to be bullet-proof. Once SOS Digital Technologies Inc is created, SOS plans to launch the first digital assets insurance company and the first cryptocurrency bank in the world, backed up by Dr Yan's technologies. This venture is urgent as about 20% of cryptocurrencies are stolen or lost every year. Such venture is highly necessary as DCEP, the sovereign cryptocurrency offered by the central Bank of China, is in its testing stage and other sovereign cryptocurrencies are coming soon." finance.yahoo.com
NYSE:SOS
by AlenCiken
3
COCA-COLA ON THE S/R ZONE🙋‍♂️ Hello Stocks Community! Coca Cola is now on the key S/R zone of 2021. You can see my prepared trade with SL and TP! More information about my trading style: I am not a pattern trader. My strategy and edge are based on volume zones where I see Big players were trading. When the market comes there, I want to enter a trade. Every day I identify key levels and key zones, then I just wait for the price to come. Hope it helps, See you next time!
NYSE:KOLong
by Asanato
2
The revival of Energy - XLE on the riseXLE has been in a range for quite some time with the fall of Oil price from the first lockdown. But as thing recover and demand for Oil is returning to somewhat normal levels, the ETF is starting to give signs of life as well. RSI well above 50 and is moving slowly into overbought territory, but this means that there is more room for the price to rise. MACD has made a crossover and the histogram is turning positive. Resistance level circa 40 has been breached.
AMEX:XLELong
by DailyChartist
ISR has received FDA 510(k) clearanceC4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer ISR has received FDA 510(k) clearance for the use of C4 Imaging’s Sirius® positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds. Sirius MRI Markers will enable Isoray’s customers to fully utilize the benefits of MRI seed localization. Brachytherapy, or internal radiation therapy, is a leading, cost-effective option for the treatment of prostate cancer. Isoray is the world’s only producer of Cesium-131, commercially known as Cesium Blu™, brachytherapy seeds. Cesium-131 is a radioactive isotope that delivers a minimally invasive and highly targeted treatment to the site of the cancer preserving healthy tissue and organs. Patients benefit from the rapid resolution of their side effects allowing them to return to their normal lives quickly. finance.yahoo.com
I
by AlenCiken
2
“Strong Buy” Penny Stock That Could Deliver Massive Returns“Strong Buy” Penny Stock That Could Deliver Massive Returns The company’s development pipeline features drug candidates under investigation as treatments for short bowel syndrome (SBS) and celiac disease (CeD), two conditions that are both dangerous and difficult to treat. 9 Meters’ flagship product, Larazotide, is in Phase 3 development for the treatment of CeD. CeD affects about 1% of the population, yet there are no approved therapies. Top-line data from the study is expected in the second half of 2021. this past December, the company announced that it had entered an agreement with EBRIS, the European Biomedical Research Institute of Salerno, to investigate Larazotide as a potential treatment for respiratory complications due to COVID-19. The other major drug in the company’s pipeline is NM-002, for SBS. The company has recently announced positive Phase 1b/2a results, with a measurable impact on disease symptoms from a compound that was well-tolerated by patients. finance.yahoo.com
N
by AlenCiken
The9 to Start the Cryptocurrencies BusinessThe9 Signed a Legally Binding Cooperation and Investment Term Sheet with Cryptocurrencies Mining Investors Led by Jianping Kong to Start the Cryptocurrencies Business The9 has begun to deploy its blockchain and cryptocurrencies business strategy. This time, we are cooperating with investors including Mr. Jianping Kong. They have rich experience and resources in the field of cryptocurrencies mining machine manufacturing and cryptocurrencies mining operation and should be able to assist The9 to launch our cryptocurrencies mining operation. Our goal is to build up cryptocurrencies mining machines for The9 that will contribute 8% to 10% of the global hash rate of Bitcoin, 10% of the global hash rate of Ethereum and 10% of the global hash rate of Grin and become one of the world's largest cryptocurrencies mining companies in terms of hash rate. This will also speed up our other cryptocurrency related businesses. It has been 12 years since the birth of Bitcoin. Pursuant to the Term Sheet, The9 will issue Class A ordinary shares and warrants to the Investors. The9 is expected to receive proceeds from the transactions contemplated under the Term Sheet in accordance with certain pre-agreed conditions, if realized. The Investors are expected to utilize their cryptocurrencies mining industry resources to assist The9 for its development of cryptocurrencies mining business. The9 will set up a new wholly owned subsidiary NBTC Limited to operate its blockchain and cryptocurrencies business. The9 will issue 8,108,100 Class A ordinary shares (equivalent to 270,270 ADSs) at US$0.1233 per Class A ordinary share (equivalent to US$3.7 per ADS) and 207,891,900 warrants, each warrant representing the right to purchase one Class A Ordinary share (equivalent to 6,929,730 ADSs assuming full exercise of warrants) to the Investors. The warrants will be divided into four equal tranches: - The exercise price of three tranches of warrants is US$0.1233 per Class A ordinary share (equivalent to US$3.7 per ADS) - The exercise price of the other tranche of warrants is US$0.2667 per Class A ordinary share (equivalent to US$8 per ADS). Each tranche of the warrants is subject to its vesting conditions including market capitalization of The9 reaching US$100 million, US$300 million, US$500 million and US$1 billion within the timeframes of 6 months, 12 months, 24 months and 36 months, respectively. If the Investors exercise all of the warrants, The9 is expected to raise an aggregate consideration of approximately US$34 million in this transaction from the Class A ordinary shares issuance consideration and warrants exercise. The9 has the right to decide whether the Investors shall make payments in the form of U.S. dollars or cryptocurrencies (including Bitcoin) in the definitive agreement. finance.yahoo.com
NASDAQ:NCTYLong
by AlenCiken
ftiv Announce Execution of Definitive Business CombinationPerella Weinberg Partners and FinTech IV Announce Execution of Definitive Business Combination Agreement Transaction Includes Commitments for a $125 Million Common Stock Private Placement from Leading Institutional Investors Including Fidelity Management & Research Company LLC, Wellington Management and Strategic Investor Korea Investment & Securities Perella Weinberg Partners’ Working Partners and Employees Will Own Approximately 50% of the Company Post-Closing The transaction reflects an implied equity value for the Company of approximately $975 million. Established, Diversified Franchise in the U.S. and Europe With approximately 560 employees. Culture and Alignment Positioned to Drive Shareholder Value The cash component of the consideration will be funded by FinTech IV’s $230 million cash in trust At closing of the transaction, PWP expects to have a debt-free balance sheet with access to additional liquidity under an undrawn revolving credit facility. The business combination is expected to close in the first half of 2021 finance.yahoo.com
F
by AlenCiken
LOAC Announces Signing of Definitive Merger AgreementLongevity Acquisition Corporation Announces Signing of Definitive Merger Agreement 4D pharma's Live Biotherapeutic Products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs At the effective time of the merger, each of LOAC's ordinary shares issued and outstanding prior to the effective time of the merger will be automatically converted into the right to receive certain per share merger consideration, and each warrant to purchase LOAC's ordinary shares and right to receive LOAC's ordinary shares that is outstanding immediately prior to the effective time of the merger will be assumed by 4D pharma and automatically converted into a warrant to purchase ordinary shares of 4D pharma and a right to receive ordinary shares of 4D pharma, payable in 4D pharma ADSs, respectively. www.prnewswire.com
L
by AlenCiken
Big Rock Partners Acquisition Corp Announces Merger with NeuroRxBig Rock Partners Acquisition Corp. Announces Merger with NeuroRx, Inc. Combined Company to Have an Estimated Post-Transaction Equity Value in Excess Of $500 Million (Excluding Potential Earnout Payments), Assuming A Share Price Of At Least $10.00 Per Share NeuroRx, Inc. is a clinical stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of COVID-19 (RLF-100 or "ZYESAMI™ (aviptadil)") and Bipolar Depression (NRX-100, 101) The transaction is expected to occur in the first or second quarter of 2021. Under the terms of the transaction, Big Rock will issue to NeuroRx's current equity holders an aggregate of 50 million shares of Big Rock common stock for their interests in NeuroRx ubject to certain conditions, an aggregate of 25 million additional shares of Big Rock common stock will be issued to NeuroRx pre-merger equity holders if, prior to December 31, 2022, (1) RLF-100 receives emergency use authorization by the FDA and (2) the FDA accepts the Company's filing of its application to approve RLF-100. In addition, subject to certain conditions, a $100 million cash earnout may be payable to NeuroRx pre-merger equity holders if, prior to December 31, 2022, either (1) FDA approval of the Company's COVID-19 Drug is obtained and the Company's COVID-19 Drug is listed in the FDA's "Orange Book" or (2) FDA approval of the Company's Antidepressant Drug Regimen is obtained and the Company's Antidepressant Drug Regimen is listed in the FDA's "Orange Book". finance.yahoo.com
B
by AlenCiken
2